Dosing
Zepbound dosage chart: a guide to the label
Zepbound contains tirzepatide. Its starting schedule is shared across approved uses, but maintenance dosing depends on the condition being treated and what you tolerate.
How to read a dosage chart
A titration chart describes a labeled schedule, not an instruction to change your own treatment. Starter doses help introduce the medicine; the prescriber selects a maintenance dose according to the indication, response, and tolerability. Calendar weeks do not override side effects or individualized instructions.
Milligrams measure the medicine dose. Milliliters measure liquid volume, and syringe units measure markings on a particular syringe. They are not interchangeable. Never use a brand-name chart to convert a compounded vial into syringe units: concentrations differ, and the pharmacist must provide product-specific instructions.
Sources: FDA concerns with unapproved GLP-1 drugs used for weight loss
Labeled schedule
The 7.5 mg and 12.5 mg steps are intermediate escalation doses, not the listed maintenance doses for weight management. More medicine is not automatically better. For sleep apnea, treatment decisions include the full sleep-care plan; this medicine should not become a reason to stop PAP therapy on your own.
| Stage or indication | Dose | Meaning |
|---|---|---|
| First 4 weeks | 2.5 mg once weekly | Initiation only, not maintenance |
| After at least 4 weeks | 5 mg once weekly | First possible weight-management maintenance dose |
| Further escalation if needed | 2.5 mg increments after at least 4 weeks per dose | Maximum 15 mg once weekly |
| Weight management | 5, 10, or 15 mg weekly | Choose with prescriber |
| Obstructive sleep apnea | 10 or 15 mg weekly | For adults with obesity and moderate-to-severe OSA |
Sources: Zepbound prescribing information
Missed doses and other instructions
Take a missed dose within 4 days (96 hours); if more than 4 days have passed, skip it. Keep at least 72 hours between doses if changing the weekly day. Oral contraceptive users should discuss a non-oral method or added barrier protection for 4 weeks after starting and for 4 weeks after each dose escalation.
The device you receive matters. Single-dose pens, multidose pens, prefilled syringes, and vials do not use one universal injection technique. Review the Instructions for Use supplied with your product, and request training when a pharmacy changes the presentation.
Sources: Zepbound prescribing information
Safety before any dose change
These medicines have boxed warnings about thyroid C-cell tumors observed in rodents; whether the same risk occurs in humans is unknown. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication. This is different from saying that every thyroid condition prevents treatment.
Review severe stomach problems, previous pancreatitis, gallbladder disease, kidney problems, diabetes-related eye disease, pregnancy plans, and all medicines with your prescriber. Insulin or sulfonylureas can increase the risk of low blood sugar when combined with these treatments. Vomiting and diarrhea can cause dehydration and kidney injury.
Severe persistent abdominal pain, inability to keep fluids down, or signs of an allergic reaction require prompt medical assessment. Do not increase a dose to overcome slow weight loss or copy another person's prescription. Tell the anesthesia team about treatment before procedures because delayed gastric emptying can affect aspiration risk.
Sources: Wegovy prescribing information, including tablets and Wegovy HD · Ozempic prescribing information · Zepbound prescribing information · Mounjaro prescribing information
Why there are several maintenance options
For weight management, the label lists 5, 10, and 15 mg as maintenance doses and directs selection according to response and tolerability. The existence of a 15 mg maximum does not mean a patient benefiting at 5 mg must eventually take it. Conversely, a starter dose that feels effective is not automatically a labeled long-term maintenance regimen. The clinician should distinguish the initiation phase from the treatment plan intended to continue.
The 7.5 and 12.5 mg strengths provide intermediate escalation steps. A discussion about remaining at a step should name the clinical reason and the exact prescription, rather than rely on an internet chart that silently treats every available strength as maintenance. For obstructive sleep apnea, the recommended maintenance options are 10 and 15 mg, so the purpose of treatment changes how the same sequence is interpreted.
Sources: Zepbound prescribing information
Assess response beyond one week's weight
A single weigh-in cannot determine whether to escalate. At review, discuss the trajectory over time, tolerability, ability to eat and drink, and the health condition being treated. Sleep-apnea care also requires coordination with the sleep clinician; a change on the scale does not establish that positive airway pressure is no longer needed. Trials report averages over many months, not a required weekly loss for each dose.
If weight has stopped falling while vomiting, severe fullness, or diarrhea is interfering with daily life, increasing solely to restart loss can miss a safety problem. Report symptoms before the next refill or escalation. Persistent severe abdominal pain, inability to keep fluids down, or signs of an allergic reaction need medical assessment rather than a routine discussion about whether to stay at the same strength.
Sources: Zepbound prescribing information
Keep escalation and catch-up calendars separate
An escalation calendar counts time at a dose; a missed-dose calendar counts hours from a scheduled or actual injection. They solve different problems. For example, taking a late dose within the 96-hour window does not remove the requirement for at least 72 hours between injections if the weekly day is changed. Write down actual dates and times so a pharmacist can check both rules.
A long interruption needs a separate restart conversation. Tell the prescriber the last dose, how many doses were missed, why treatment stopped, and whether symptoms continue. Do not use the former maintenance strength simply because an unopened supply remains. If the pharmacy changes the presentation, obtain training for the new device as well. A calendar entry cannot substitute for the product's Instructions for Use.
Sources: Zepbound prescribing information
Sources and evidence
Sources checked October 2, 2026. Prescribing information supports medication facts; provider pages support advertised services. Offers and labels can change.